SynKIR-310 for Relapsed/Refractory B-NHL
Phase 1
18
about 4.2 years
18+
5 sites in CO, GA, KS +2
About this study
Researchers are testing the safety and preliminary effectiveness of SynKIR-310, a medication given intravenously, in adults with relapsed or refractory B-cell non-Hodgkin lymphoma. The trial will last approximately 1521 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive SynKIR-310
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
Primary: Recommended Phase 2 Dose (RP2D)
Secondary: PK profile of SynKIR-310, Preliminary efficacy : Objective response rate (ORR), Preliminary efficacy: Complete response rate (CR), Preliminary efficacy: Duration of response (DOR)
Oncology